Should patients with advanced colorectal cancer and ECOG 3/4 be treated with chemotherapy? (2013)
- Authors:
- USP affiliated author: HOFF, PAULO MARCELO GEHM - FM
- School: FM
- Subjects: REGRESSÃO LOGÍSTICA; NEOPLASIAS COLORRETAIS (QUIMIOTERAPIA); PROGNÓSTICO
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: European Journal of Cancer
- ISSN: 0959-8049
- Volume/Número/Paginação/Ano: v. 49, supl 2, p. S288, res. 1369, 2013
- Conference title: European Cancer Congress 2013 Abstract Book
-
ABNT
CROSARA, M. A. T. et al. Should patients with advanced colorectal cancer and ECOG 3/4 be treated with chemotherapy?. European Journal of Cancer. Oxford: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 28 jun. 2022. , 2013 -
APA
Crosara, M. A. T., Alves, M. F. S., Alex, A. K., Sabbaga, J., Hoff, P. M. G., Riechelmann, R., et al. (2013). Should patients with advanced colorectal cancer and ECOG 3/4 be treated with chemotherapy? European Journal of Cancer. Oxford: Faculdade de Medicina, Universidade de São Paulo. -
NLM
Crosara MAT, Alves MFS, Alex AK, Sabbaga J, Hoff PMG, Riechelmann R, Marques DF, Ferrari AC. Should patients with advanced colorectal cancer and ECOG 3/4 be treated with chemotherapy? European Journal of Cancer. 2013 ; 49 S288.[citado 2022 jun. 28 ] -
Vancouver
Crosara MAT, Alves MFS, Alex AK, Sabbaga J, Hoff PMG, Riechelmann R, Marques DF, Ferrari AC. Should patients with advanced colorectal cancer and ECOG 3/4 be treated with chemotherapy? European Journal of Cancer. 2013 ; 49 S288.[citado 2022 jun. 28 ] - TSC2 rare germline variants in non-tuberous sclerosis patients with neuroendocrine neoplasias
- Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib
- Do we need another antiangiogenesis agent for colorectal cancer: are bevacizumab and aflibercept the same?
- Building research capacity and clinical trials in developing countries
- Living better or living longer? perceptions of patients (PTS) and health care professionals (HCP) in ONCOLOGY
- Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III, in patients with advanced solid malignancies
- Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury
- Antiangiogenic Drugs for Colorectal Cancer: Exploring New Possibilities
- Análise restrospectiva de desfechos clínicos e fatores prognósticos em pacientes com carcinomatose meníngea
- Revisão de processos reduz tempo de implementação de estudos clínicos no Instituto do Câncer do Estado de São Paulo
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
